Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Clinical Pharmacology in Drug Development
|
April 20, 2026
Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
Ronilda D'Cunha, Yuli Qian, Shuai Hao, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 18, 2024
Transdifferentiation occurs without resetting development-specific DNA methylation, a key determinant of full-function cell identity
Ahmed Radwan, Jason Eccleston, Ofra Sabag, et al.
Hepatology (Baltimore, Md.)
|
April 20, 2017
Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity
Christopher Koh, Sasan Sakiani, Pallavi Surana, et al.
The American Journal of Gastroenterology
|
September 6, 2022
Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis
Julian Hercun, Mazen Noureddin, Nabil Noureddin, et al.
Clinical and Experimental Dermatology
|
May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial
Stephen Tyring, Angela Moore, Akimchi Morita, et al.
Journal of Crohn'S & Colitis
|
April 14, 2026
Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization
Tim Raine, James D Lewis, Gareth C Parkes, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2025
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Remo Panaccione, Séverine Vermeire, Silvio Danese, et al.
Nature Cancer
|
March 14, 2023
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers
Lei Shi, William Shen, Mindy I Davis, et al.
Science (New York, N.Y.)
|
July 11, 2024
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity
Meng-Ju Wu, Hiroshi Kondo, Ashwin V Kammula, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Clinical Pharmacology in Drug Development
|
April 20, 2026
Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
Ronilda D'Cunha, Yuli Qian, Shuai Hao, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 18, 2024
Transdifferentiation occurs without resetting development-specific DNA methylation, a key determinant of full-function cell identity
Ahmed Radwan, Jason Eccleston, Ofra Sabag, et al.
Hepatology (Baltimore, Md.)
|
April 20, 2017
Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity
Christopher Koh, Sasan Sakiani, Pallavi Surana, et al.
The American Journal of Gastroenterology
|
September 6, 2022
Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis
Julian Hercun, Mazen Noureddin, Nabil Noureddin, et al.
Clinical and Experimental Dermatology
|
May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial
Stephen Tyring, Angela Moore, Akimchi Morita, et al.
Journal of Crohn'S & Colitis
|
April 14, 2026
Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization
Tim Raine, James D Lewis, Gareth C Parkes, et al.
The Lancet. Gastroenterology & Hepatology
|
May 10, 2025
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Remo Panaccione, Séverine Vermeire, Silvio Danese, et al.
Nature Cancer
|
March 14, 2023
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers
Lei Shi, William Shen, Mindy I Davis, et al.
Science (New York, N.Y.)
|
July 11, 2024
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity
Meng-Ju Wu, Hiroshi Kondo, Ashwin V Kammula, et al.
Page
of 1